Associate Professor of Psychiatry, Massachusetts General Hospital
Psychiatry
Dr. George I. Papakostas, MD
|
|
Give Review
George Papakostas practices Psychiatry. He went to NYU School of Medicine. George Papakostas is a published doctor and has 101 publications published. The lastest was: 'Left hemispheric dominance of epileptiform discharges.'
Publications
- Relationship between placebo response rate and clinical trial outcome in bipolar depression.
- The pro-inflammatory profile of depressed patients is (partly) related to obesity.
- Efficacy of ziprasidone monotherapy in patients with anxious depression: A 12-week, randomized, double-blind, placebo-controlled, sequential-parallel comparison trial.
- The nature of placebo response in clinical studies of major depressive disorder.
- MDDScore: confirmation of a blood test to aid in the diagnosis of major depressive disorder.
- Updates and trends in the treatment of major depressive disorder.
- A Double-blind, randomized, placebo-controlled clinical trial of S-adenosyl-L-methionine (SAMe) versus escitalopram in major depressive disorder.
- Association between physician beliefs regarding assigned treatment and clinical response: Re-analysis of data from the Hypericum Depression Trial Study Group.
- Predictors of placebo response in bipolar depression.
- Psychomotor symptoms and treatment outcomes of ziprasidone monotherapy in patients with major depressive disorder: a 12-week, randomized, double-blind, placebo-control...
- Effect of adjunctive L-methylfolate 15 mg among inadequate responders to SSRIs in depressed patients who were stratified by biomarker levels and genotype: results from...
- Pooled analysis of adjunct extended-release quetiapine fumarate in patients with major depressive disorder according to ongoing SSRI or SNRI treatment.
- Cognitive symptoms in patients with major depressive disorder and their implications for clinical practice.
- Efficacy of desvenlafaxine 50 mg compared with placebo in patients with moderate or severe major depressive disorder: a pooled analysis of six randomized, double-blind...
- Quetiapine XR monotherapy in major depressive disorder: a pooled analysis to assess the influence of baseline severity on efficacy.
- RELATIONSHIP BETWEEN SLEEP DISTURBANCE AND DEPRESSION, ANXIETY, AND FUNCTIONING IN COLLEGE STUDENTS.
- Assessment of a multi-assay, serum-based biological diagnostic test for major depressive disorder: a Pilot and Replication Study.
- A 12-week, randomized, double-blind, placebo-controlled, sequential parallel comparison trial of ziprasidone as monotherapy for major depressive disorder.
- Concentration and bioaccumulation of organochlorine pesticide residues in herons and their prey in wetlands of Thermaikos Gulf, Macedonia, Greece.
- Left hemispheric dominance of epileptiform discharges.
- Mercury in feathers of Squacco Heron (Ardeola ralloides) chicks in relation to age, hatching order, growth, and sampling dates.
- Epilepsy and the ancient world: from the magic beliefs of the Babylonians to the Hippocratic scientific thinking.
- NEO-FFI factor scores as predictors of clinical response to fluoxetine in depressed outpatients.
- Elevated cholesterol levels associated with nonresponse to fluoxetine treatment in major depressive disorder.
- Treatment-resistant depression and Axis II comorbidity.
- A survey of prescribing preferences in the treatment of refractory depression: recent trends.
- Functioning and interpersonal relationships as predictors of response in treatment-resistant depression.
- Lithium augmentation of nortriptyline for subjects resistant to multiple antidepressants.
- Nortriptyline for treatment-resistant depression.
- Behavioral and emotional disturbances in the offspring of depressed parents with anger attacks.
- Somatic symptoms in treatment-resistant depression.
- Serum cholesterol in treatment-resistant depression.
- Serum cholesterol and serotonergic function in major depressive disorder.
- Axis III disorders in treatment-resistant major depressive disorder.
- Switching to bupropion in fluoxetine-resistant major depressive disorder.
- Hopelessness and suicidal ideation in outpatients with treatment-resistant depression: prevalence and impact on treatment outcome.
- A pilot, open study of sertraline in outpatients with treatment-resistant depression (TRD) or with a history of TRD who responded but later relapsed.
- Early-onset depression and the emotional and behavioral characteristics of offspring.
- A historical inquiry into the appropriateness of the term "panic disorder".
- S-adenosyl-methionine in depression: a comprehensive review of the literature.
- Psychiatric comorbidity as a predictor of clinical response to nortriptyline in treatment-resistant major depressive disorder.
- Quality of life assessments in major depressive disorder: a review of the literature.
- Treatment-related adverse events and outcome in a clinical trial of fluoxetine for major depressive disorder.
- Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder.
- Cholesterol in mood and anxiety disorders: review of the literature and new hypotheses.
- Somatic symptoms as predictors of time to onset of response to fluoxetine in major depressive disorder.
- Anxiety and somatic symptoms as predictors of treatment-related adverse events in major depressive disorder.
- Psychosocial functioning in patients with treatment resistant depression.
- Serum cholesterol in the continuation phase of pharmacotherapy with fluoxetine in remitted major depressive disorder.
- Continuation cognitive-behavioural therapy maintains attributional style improvement in depressed patients responding acutely to fluoxetine.
- Serum folate, vitamin B12, and homocysteine in major depressive disorder, Part 1: predictors of clinical response in fluoxetine-resistant depression.
- Serum folate, vitamin B12, and homocysteine in major depressive disorder, Part 2: predictors of relapse during the continuation phase of pharmacotherapy.
- Comorbid medical illness and relapse of major depressive disorder in the continuation phase of treatment.
- Psychosocial functioning during the treatment of major depressive disorder with fluoxetine.
- Obesity among outpatients with major depressive disorder.
- S-adenosyl-L-methionine (SAMe) as an adjunct for resistant major depressive disorder: an open trial following partial or nonresponse to selective serotonin reuptake in...
- Effects of psychiatric disorders and psychotropic medications on prolactin and bone metabolism.
- The relationship between serum folate, vitamin B12, and homocysteine levels in major depressive disorder and the timing of improvement with fluoxetine.
- Adjunctive atomoxetine for residual fatigue in major depressive disorder.
- Empirical testing of two models for staging antidepressant treatment resistance.
- Augmentation of standard antidepressants with atypical antipsychotic agents for treatment-resistant major depressive disorder.
- An open study of triiodothyronine augmentation of selective serotonin reuptake inhibitors in treatment-resistant major depressive disorder.
- Cardiovascular risk factors may moderate pharmacological treatment effects in major depressive disorder.
- Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder.
- Brain MRI white matter hyperintensities and one-carbon cycle metabolism in non-geriatric outpatients with major depressive disorder (Part II).
- Brain MRI white matter hyperintensities and one-carbon cycle metabolism in non-geriatric outpatients with major depressive disorder (Part I).
- Clinical characteristics of depressed patients with comorbid diabetes mellitus.
- Anger attacks in major depressive disorder and serum levels of homocysteine.
- Dopaminergic-based pharmacotherapies for depression.
- A meta-analysis of early sustained response rates between antidepressants and placebo for the treatment of major depressive disorder.
- A description of next-step switching versus augmentation practices for outpatients with treatment-resistant major depressive disorder enrolled in an academic specialty...
- Brain white-matter hyperintensities and treatment outcome in major depressive disorder.
- The combination of duloxetine and bupropion for treatment-resistant major depressive disorder.
- A survey of antidepressant prescribing practices in major depression with comorbid attention-deficit hyperactivity disorder.
- A meta-analysis of clinical trials comparing milnacipran, a serotonin--norepinephrine reuptake inhibitor, with a selective serotonin reuptake inhibitor for the treatme...
- Differences in cognitive factors between "true drug" versus "placebo pattern" response to fluoxetine as defined by pattern analysis.
- Somatic symptoms in outpatients with major depressive disorder treated with fluoxetine.
- Problem-solving ability and comorbid personality disorders in depressed outpatients.
- Serum prolactin levels among outpatients with major depressive disorder during the acute phase of treatment with fluoxetine.
- Symptoms of fatigue and sleepiness in major depressive disorder.
- Treatment-resistant depression.
- Consensus statement and research needs: the role of dopamine and norepinephrine in depression and antidepressant treatment.
- Resolution of sleepiness and fatigue in major depressive disorder: A comparison of bupropion and the selective serotonin reuptake inhibitors.
- Major depressive disorder: similar remission rates with bupropion, sertraline, or venlafaxine following treatment switch from citalopram.
- Timing of clinical improvement and symptom resolution in the treatment of major depressive disorder.
- A metaanalysis of clinical trials comparing moclobemide with selective serotonin reuptake inhibitors for the treatment of major depressive disorder.
- A cross-sectional study of the prevalence of cognitive and physical symptoms during long-term antidepressant treatment.
- Extreme response style in recurrent and chronically depressed patients: change with antidepressant administration and stability during continuation treatment.
- A meta-analysis of clinical trials comparing the serotonin (5HT)-2 receptor antagonists trazodone and nefazodone with selective serotonin reuptake inhibitors for the t...
- Hopelessness as a predictor of non-response to fluoxetine in major depressive disorder.
- Relative antidepressant efficacy of bupropion and the selective serotonin reuptake inhibitors in major depressive disorder: gender-age interactions.
- Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating m...
- Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis.
- Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of anxiety symptoms in major depressive disorder: a meta-analysis of individual ...
- A detailed examination of cytokine abnormalities in Major Depressive Disorder.
- Antidepressant dose reduction and the risk of relapse in major depressive disorder.
- A meta-analysis of clinical trials comparing reboxetine, a norepinephrine reuptake inhibitor, with selective serotonin reuptake inhibitors for the treatment of major d...
- Limitations of contemporary antidepressants: tolerability.
- Treatment of SSRI-resistant depression: a meta-analysis comparing within- versus across-class switches.
- Comparing the rapidity of response during treatment of major depressive disorder with bupropion and the SSRIs: a pooled survival analysis of 7 double-blind, randomized...
Schools
New York University
Carney Hospital
Mass General Hospital
McLean Hospital
Doctors Specialties
- Psychiatry
Accepted Insurances
Education
-
Massachusetts General Hospital -
NYU School of Medicine
Hospital
-
Massachusetts General Hospital
Helpful Reviews
Similar Doctors
|
|
Dr. Helen Riess, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Maurizio Fava, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lucia E. Ciurea, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Carol E. Weichert, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kyle C. Walker, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Adam P. Stern, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Elizabeth M. Licalzi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Djordje N. Koldzic, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Dana S. Rubin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Esther R. Valdez, MD |
|
|
Dr. Raymond Serrano, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gregory F. Oxenkrug, MD
This Doctor is OpenDoctor Recommended.
|